The supply gap as a clinical event
Real-world persistence figures, with their definitions stated, because the definitions are doing most of the work.
The Ledger
Page 2 of 25 of this archive, newest first.
Page 2
Continued treatment against continued placebo: the comparison that settled it
The evidence on stopping is better than the evidence on almost anything else in this field, because somebody deliberately randomised it.
Nigeria caps exenatide prescribing to 23 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
The United Arab Emirates declines to reimburse tirzepatide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
Six words a verification badge would need to mean anything
A badge asserts that something was tested. It does not assert what, when, on whose sample, by what method, or whether the lot on sale is the lot that was tested.
South Korea declines to reimburse liraglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
Spain caps semaglutide prescribing to 3 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
Australia declines to reimburse exenatide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
What STEP 2 tells us about maintenance, and what it does not
What the labels permit, what clinicians do, and the size of the gap between them.
The badge economy, and what it is actually certifying
Every step between the laboratory report and the product page removes information, and the badge is the last step.
The supply gap as a clinical event
Why the reason for stopping changes what happens afterwards.
Same material, different gradients, different answers
Two years ago we ran an anonymised version of this comparison and promised a named one. This is it, with every method printed in full.
An interlaboratory comparison nobody had run
Two years ago we ran an anonymised version of this comparison and promised a named one. This is it, with every method printed in full.
Poland declines to reimburse tirzepatide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
Germany caps semaglutide prescribing to 14 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
Argentina caps semaglutide prescribing to 17 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
The supply gap as a clinical event
Cost is the modal reason for discontinuation in every dataset we have seen, and it is absent from the clinical literature.
Ireland declines to reimburse liraglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
The named comparison we promised two years ago
The Journal submitted split samples from single lots to three assay services, under names unconnected to this publication, and published each method alongside each result.
South Africa caps exenatide prescribing to 20 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.